


Melanoma

MARKET*



7

Immune Checkpoint Inhibitors**



1

Cancer Vaccine




1

Cell Therapy

+6 Proteins (*interferon alfa*) are marketed


Drug Pipeline : Molecule Type



Recent Clinical Success




Strategic Alliance between MSD and Microbiotica for a **live biotherapeutic product** in PhIb



April 2023




Positive top-line data from Phase I for OBX-115, a **TIL gene therapy**



December 2023



FDA has approved the first **cell therapy (TIL)**, the lifileucel from Iovance Biotherapeutics



February 2024